(1998). (2001b) HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer. Cancer Res 61: 8452–8458 Early Breast Cancer Trialists’ Collaborative Group
(1993). Distribution of estrogen receptor in ductal carcinoma in situ of the breast. Surgery 113: 134–137
(2002). Estrogen receptor expression as a predictive marker of the effectiveness of tamoxifen in the treatment of
(2001). MIB1 proliferation index in breast infiltrating carcinoma: comparison with other proliferative markers and association with new biological prognostic factors. Histol Histopathol 16: 399–406 Harper-Wynne
(2000). Prediction of clinical outcome from primary tamoxifen by expression of biologic markers in breast cancer patients.
(2002). The evolution of tamoxifen therapy in breast cancer: selective oestrogen-receptor modulators and downregulators.